SCHEMBL10043909

SCHEMBL10043909

Cc1cc2c(cn1)cc(-c1cc(C(=O)Nc3cnccn3)ccc1C)c(=O)n2C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPK14 Q16539 8/20 0.44
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
KMT2A Q03164 1/20 0.43
SYK P43405 1/20 0.41
LCK P06239 1/20 0.41
MAPK13 O15264 1/20 0.41
RAF1 P04049 1/20 0.41
PDGFRA P16234 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
MAPK12 P53778 1/20 0.41
KCNH2 Q12809 1/20 0.41
MAPK11 Q15759 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043912 0.89 NPC1 (0.51) RAB9ASMN1; SMN2MAPK14NPC1TP53
SCHEMBL10043900 0.89 NPC1 (0.46) RAB9ASMN1; SMN2MAPK14NPC1MAPT
SCHEMBL10043926 0.86 MAPK14 (0.45) MAPK14SYKLCKMAPK13RAF1
SCHEMBL502061 0.86 CNR1 (0.48) RAB9ASMN1; SMN2MAPK14NPC1TP53
SCHEMBL10043916 0.85 MAPK14 (0.47) RAB9AMAPK14NPC1TP53KMT2A
SCHEMBL10043906 0.85 MAPK14 (0.45) RAB9AMAPK14NPC1SYKLCK
SCHEMBL10043897 0.85 ALDH1A1 (0.59) RAB9ASMN1; SMN2MAPK14NPC1TP53
SCHEMBL10043919 0.85 NPC1 (0.50) RAB9AMAPK14NPC1SYKMAPK13
SCHEMBL10043911 0.84 MAPK14 (0.62) SMN1; SMN2MAPK14KMT2ASYKLCK
SCHEMBL10043907 0.84 RAB9A (0.51) RAB9ASMN1; SMN2MAPK14NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885SMN1; SMN2 2302/4885MAPK14 117/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885SMN1; SMN2 2302/4885MAPK14 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.